<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02917720</url>
  </required_header>
  <id_info>
    <org_study_id>ELN-002</org_study_id>
    <secondary_id>2015-004998-33</secondary_id>
    <nct_id>NCT02917720</nct_id>
  </id_info>
  <brief_title>2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First or Second Unsuccessful Treatment Discontinuation in CML</brief_title>
  <acronym>NAUT</acronym>
  <official_title>Multicenter Prospective Trial After First or Second Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd or 3rd Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European LeukemiaNet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>European LeukemiaNet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the study is the assessment of duration of major molecular response (MMR) or
      better at 12 and 36 months after stopping tyrosine kinase inhibitors (TKI) therapy a second
      or third time in patients with at least three years prior TKI treatment comprising at least
      two years of nilotinib treatment within this trial and maintained stable MR4 (BCR-ABL ratio
      &lt;0,01% on international Scale (IS) for at least one year and MR4.5 (BCR-ABL ratio &lt;0,0032% on
      IS) for at least 6 months:

        -  who failed a first stop in the EURO-SKI study (standardized criteria)

        -  who failed a first or second stop outside the EURO-SKI study but would have had
           fulfilled same eligible criteria and were stopped according to EURO-SKI rules

        -  who failed a first or second stop outside the EURO-SKI study without fulfilling EURO-SKI
           rules
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposal is to re-treat patients with a minimum of two years with nilotinib 2x300 mg/d
      resulting in total of at least three years TKI treatment who show recurrent disease after
      unsuccessful first or second stop after TKI treatment in or outside the EURO-SKI study.

      If MR4 or better is re-achieved and maintained for at least one year and MR4.5 or better is
      re-achieved and maintained for at least 6 months, patients will be eligible for a second stop
      attempt within this study. For MR4, three consecutive PCRs with MR4 or deeper should be
      measured within one year and for MR4.5, two PCRs during 6 months should demonstrate a MR4.5.

      Patients who exhibited hematological relapse after the first stop attempt will not be
      eligible for a second stop attempt within this study.

      After inclusion, 3 monthly monitoring will be performed under nilotinib treatment within the
      trial. Patients fulfilling the criteria mentioned above will then enter the screening phase.

      After verification of MR4.5, TKI treatment will be stopped and patients followed in the same
      manner as described in EURO-SKI (monthly PCRs for 6 months, 6-weekly PCRs 7-12 months after
      stopping, thereafter 3-monthly). If MMR is lost (BCR-ABL &gt;0.1% (IS)), TKI treatment will once
      again be restarted; here the same TKI (nilotinib) is recommended.

      It is assumed that after failure of first (or second) stop a switch to treatment with 2GTKI
      may increase the chance of stopping a second (or third) time [Legros et al. Blood 2012; Rea
      et al. Blood 2014] It is expected that the rate of a successful second (or third) stop at 12
      and 36 months is more than 25%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of duration of MMR or better at 12 months after stopping TKI therapy a second or third time</measure>
    <time_frame>12 months after stopping</time_frame>
    <description>Assessment of duration of MMR or better at 12 months after stopping TKI therapy a second time in patients with at least three years prior TKI treatment comprising at least two years of nilotinib treatment within this trial and maintained stable MR4 for at least one year and MR4.5 for at least 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life (QoL) profiles under nilotinib treatment and comparison with previous TKI therapy before switch and after stopping</measure>
    <time_frame>5 years</time_frame>
    <description>To investigate QoL changes over time in relapse-free patients without TKI re-start as measured by the EORTC QLQ-C30 and CML 24 (one combined questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of clinical and biological factors correlating with the persistence of MMR or better after stopping TKI</measure>
    <time_frame>6 months after stopping</time_frame>
    <description>Proportion of high risk patients according to the risk score at 6 months after stopping TKI;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival is calculated from the date of 2nd stop of TKI treatment until the date of death irrespective of the cause of death. Patients still alive at the date of analysis will be censored at the date of last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-achievement of MR4.5 after restart of therapy</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of molecular response after 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade 1 through grade 5 adverse events (AEs) that are related to study drug, graded according to NCI CTCAE Version 3.0</measure>
    <time_frame>3 years</time_frame>
    <description>Assessment of incidence of any AEs (e.g. from musculoskeletal system) that arise after stopping TKI treatment a second time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of duration of MMR or better</measure>
    <time_frame>36 months after stopping</time_frame>
    <description>Assessment of duration of MMR or better at 36 months after stopping TKI therapy a second or third time in patients with at least three years prior TKI treatment comprising at least two years of nilotinib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with grade 1 through grade 5 adverse events (AEs) that are related to study drug, graded according to NCI CTCAE Version 3.0</measure>
    <time_frame>2 years treatment with nilotinib 300 mg/bid</time_frame>
    <description>Assessment of incidence of any AEs (e.g. from musculoskeletal system) that arise after stopping TKI treatment a second time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimation of progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression-free survival is defined as overall survival plus the additional events progression to accelerated phase or blast crisis that also terminate PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of clinical and biological factors correlating with the persistence of MMR or better after 6 months</measure>
    <time_frame>6 months after stopping</time_frame>
    <description>Proportion of female patients without molecular relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>TKI-stop, pre-treatment with nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment after unsuccessful 1st or 2nd discontinuation at least two year with nilotinib (300 mg/bid). In total, retreatment with TKI for at least 3 years before entering screening for stopping phase is warranted. Clinical monitoring every 3 months during this 2 years.
Patients who re-achieved and maintained MR4 for at least 12 months and MR4.5 for at least 6 months can enter screening phase for TFR .If MR4.5 is confirmed by an validated laboratory, patient may enter stopping phase of the study. Patient not fulfilling these criteria can be screened again every 3 months until month 48. After TKI-stop hematological monitoring and quantitative PCR of BCR/ABL1 (month 1-6 after stopping: monthly; month 7-12 after stopping: every 1.5 months, thereafter once every three months, for 3 years in total.
Relapse is defined as BCR-ABL1 &gt; 0.1% on IS at a single time point (loss of MMR) In case of relapse restart of TKI. In general, the same TKI (nilotinib) as before second stop is recommended</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TKI discontinuation</intervention_name>
    <description>2nd or 3rd TKI stop after pre-treatment with nilotinib.</description>
    <arm_group_label>TKI-stop, pre-treatment with nilotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>Pre-treatment with nilotinib 300 mg/bid for 2 years</description>
    <arm_group_label>TKI-stop, pre-treatment with nilotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with Ph chromosome and/or the BCR-ABL (either b3a2 and /or b2a2) fusion gene
             positive CML

          -  CML in CP having failed a prior attempt to stop imatinib or other TKIs therapy either
             within EURO-SKI or not

          -  Pretreatment at least one year with any TKI after 1st stop

          -  Written informed consent

        Exclusion Criteria:

          -  Previous hematological relapse after first stop of TKI.

          -  Failure to any TKI at any time during CML treatment according to current ELN criteria

          -  Previous planned or performed allo SCT

          -  Previous AP/BC at any time in the history of the disease

          -  High cardiac risk according to ESC score (≥ 10 Points)

          -  Impaired cardiac function including any of the following:

          -  Use of a ventricular paced pacemaker; congenital long QT syndrome or family history
             of; history or presence of significant ventricular or atrial tachyarrhythmias;
             clinically significant resting bradycardia (&lt;50 bpm); QTcF &gt;450 msec at baseline,
             myocardial infarction before baseline; other clinically significant heart disease
             (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension).

          -  Treatment with inhibitors of CYP3A4 or medications that have been well documented to
             prolong the QT interval is contraindicated.

          -  History of acute pancreatitis within one year of study entry or medical history of
             chronic pancreatitis.

          -  Positive hepatitis B virus serology test or HBV infection

          -  Any other malignancy except if neither clinically significant nor requires active
             intervention.

          -  Severe or uncontrolled medical conditions (i.e., uncontrolled diabetes, acute or
             chronic liver disease, pancreatic, or severe renal disease unrelated to tumor, active
             or uncontrolled infection).

          -  Women who are pregnant, breast feeding, or of childbearing potential without a
             negative serum pregnancy test at baseline. Male or female patients of childbearing
             potential unwilling to use an effective barrier contraceptive method
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Geiselhart</last_name>
    <role>Study Chair</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Saußele, Prof. Dr. med.</last_name>
    <phone>+49 621 383</phone>
    <phone_ext>6966</phone_ext>
    <email>naut@medma.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79108</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelius Waller, Prof.Dr.med</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>34220</phone_ext>
      <email>cornelius.waller@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Heiko Becker, Dr.med.</last_name>
      <phone>+49 761 270</phone>
      <phone_ext>34010</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Saußele</last_name>
      <phone>+49621383</phone>
      <phone_ext>0</phone_ext>
      <email>susanne.saussele@medma.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ambulantes Onkologie Zentrum Ansbach MVZ GmbH</name>
      <address>
        <city>Ansbach</city>
        <state>Bavaria</state>
        <zip>91522</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Jost, PD Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>NRW</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Könecke, PD Dr. med.</last_name>
      <email>Koenecke.Christian@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Arnold Ganser, Prof. Dr. med.</last_name>
      <email>Ganser.Arnold@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim H. Brümmendorf, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg.</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Klausmann, Dr. med.</last_name>
      <phone>+49 (0)6021 3427</phone>
      <phone_ext>80</phone_ext>
      <email>info@studien-zentrum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Kiani, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp le Coutre, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steffen Dörfel, Dr. med.</last_name>
      <phone>0351 795 155</phone>
      <phone_ext>0</phone_ext>
      <email>doerfel@onkozentrum.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Göhler, Dr. med.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Esslingen</city>
        <zip>73728</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Eckert, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum für Hämatologie und Onkologie Bethanien</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Tesch, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Onkologische Kooperation Harz</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Oliver Zahn, Dr. med.</last_name>
      <phone>05321 686102</phone>
    </contact>
    <contact_backup>
      <last_name>Timo Kambach, Dr. med.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald - Innere Medicin C - Hämatologie und Onkologie</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Andreas Schmidt, Prof. Dr. med.</last_name>
      <phone>03834 86</phone>
      <phone_ext>6698</phone_ext>
      <email>onkologie@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale)</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haifa Kathrin Al-Ali, PD Dr. med.</last_name>
      <phone>0345 557</phone>
      <phone_ext>7002</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Onkologie</name>
      <address>
        <city>Heilbronn</city>
        <zip>74072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Dengler, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hochhaus</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Kempten - Oberallgäu GmbH</name>
      <address>
        <city>Kempten</city>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Onkologie und Hämtologie</name>
      <address>
        <city>Köln</city>
        <zip>50677</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Tilman Steinmetz, Dr. med.</last_name>
      <phone>0221 931 8220</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Philipps-Universität</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Burchert, Prof.Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostalb, Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr. med.</last_name>
      <phone>07171 701 1302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Junghanß, Prof.Dr.med.</last_name>
    </contact>
    <contact_backup>
      <last_name>Brigitte Kragl, Dr.med.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul la Rosée, Prof. Dr. med.</last_name>
      <phone>09772 193 4001</phone>
    </contact>
    <contact_backup>
      <last_name>Christof Burkart, Dr. med.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, locatie VUmc</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Janssen, MD, PhD</last_name>
      <phone>+31 20 4442604</phone>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TKI discontinuation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

